Home > Riviste > Minerva Medica > Fascicoli precedenti > Articles online first > Minerva Medica 2020 Oct 26

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi PROMO
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Permessi
Per citare questo articolo

 

 

Minerva Medica 2020 Oct 26

DOI: 10.23736/S0026-4806.20.07054-8

Copyright © 2020 EDIZIONI MINERVA MEDICA

lingua: Inglese

COVID-19: a user’s guide, status of the art, and an original proposal to terminate viral recurrence

Giovanni C. ACTIS 1 , Davide G. RIBALDONE 2, Sharmila FAGOONEE 3, Rinaldo PELLICANO 4

1 Independent Academic Gastroenterologist, Turin General Hospitals, Turin, Italy; 2 Department of Medical Sciences, University of Turin, Turin, Italy; 3 Institute for Biostructure and Bioimaging, National Research Council, Molecular Biotechnology Center, Turin, Italy; 4 Unit of Gastroenterology, Molinette-SGAS Hospital, Turin, Italy


PDF


The world is now entering its 9th month of combat against a pandemic of deadly pneumonia. Started out from China in December 2019, the disease has been declared as caused by infection with a so far unknown RNA Coronavirus of the respiratory family, then named severe acute respiratory syndrome coronavirus (SARS)-CoV-2. In the absence of a vaccine, and with scientists still struggling for an effective therapy, COVID-19 (the SARS-dependent syndrome) carries up to now, a death toll of more than 590,000 (July 18,2020) undermining jobs and finance of contemporary society in all continents. Social distancing, the only measure hitherto shown to restrain virus spread, has been progressively loosened from May 2020 in some countries, leaving us in the fear of repeat attacks from the unchecked virus. We discuss the problem and propose to tentatively boost the anti-virus cell machinery by using lab-made viral mimics to engage cell receptors.


KEY WORDS: SARS-CoV-2; 2019-nCoV; Poly(I:C); Poly-ICLC; Hiltonol

inizio pagina